BBIO Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of -82.06%. BridgeBio Pharma, Inc.'s return on equity of -- beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

BridgeBio Pharma, Inc. has a consensus price target of $84.65, signalling upside risk potential of 13.23%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.43%. Given that BridgeBio Pharma, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

BridgeBio Pharma, Inc. has a beta of 1.256, which suggesting that the stock is 25.58% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 40.25x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of 21.32%. BridgeBio Pharma, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.

BridgeBio Pharma, Inc. has a consensus price target of $84.65, signalling upside risk potential of 13.23%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Pfizer Inc. is more attractive than BridgeBio Pharma, Inc..

BridgeBio Pharma, Inc. has a beta of 1.256, which suggesting that the stock is 25.58% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 40.25x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of 38.89%. BridgeBio Pharma, Inc.'s return on equity of -- beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

BridgeBio Pharma, Inc. has a consensus price target of $84.65, signalling upside risk potential of 13.23%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that BridgeBio Pharma, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

BridgeBio Pharma, Inc. has a beta of 1.256, which suggesting that the stock is 25.58% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 40.25x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of -23.49%. BridgeBio Pharma, Inc.'s return on equity of -- beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.

BridgeBio Pharma, Inc. has a consensus price target of $84.65, signalling upside risk potential of 13.23%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $60.50 which suggests that it could grow by 35.17%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than BridgeBio Pharma, Inc..

BridgeBio Pharma, Inc. has a beta of 1.256, which suggesting that the stock is 25.58% more volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.462%.

BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 40.25x versus 3.70x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.